Abstract: 3-Nitro-1H-1,2,4-triazole-and 2-nitro-1H-imidazole-based amides with an aryloxyphenyl core were synthesized and evaluated as antitrypanosomal agents. All 3-nitrotriazolebased derivatives were extremely potent anti-T. cruzi agents at sub nM concentrations and exhibited a high degree of selectivity for the parasite. The 2-nitroimidazole analogs were only moderately active against T. cruzi amastigotes and exhibited low selectivity. Both types of compound were active against L. donovani axenic amastigotes with excellent selectivity for the parasite, whereas three 2-nitroimidazole-based analogs were also moderately active against infected macrophages. However, no compound demonstrated selective activity against T.b.
Introduction
Parasitic infections caused by trypanosomatids constitute a major health problem in mainly resource poor countries around the world and diseases acquired by such infections are considered 'neglected' because they have received limited funding for discovery, development and delivery of new treatments. Amongst neglected tropical diseases (NTD) 1 , human African trypanosomiasis . It is estimated that together these three insect transmitted diseases are responsible for more than 110,000 deaths per year [2] .
Although the incidence of T. cruzi infection has significantly declined recently due to implementation of vector control initiatives, the number of cases in non-endemic sites (United States, Australia, Europe and Japan) is rising, primarily due to international population migration and contaminated blood transfusions [3, 4] .
The treatment of neglected diseases is based on pharmaceuticals with poor efficacy, significant side effects, high cost, poor oral bioavailability requiring a parenteral administration, long treatment course and emergence of resistance. Thus, severe toxicity and long treatment requirements coupled with limited efficacy are associated with nifurtimox (Nfx) and benznidazole (Bnz), the two currently used medications for Chagas disease [5, 6] . Similarly, drugs used to treat HAT and leishmaniasis are highly toxic (e.g. melarsoprol, antimonials), or require i.v. administration (e.g. melarsoprol, suramin, DFMO, antimonials) resulting in severe side effects, or are of high cost (e.g. DFMO, liposomal amphotericin B, miltefosine, and 4 paromomycin) [7] [8] [9] . Therefore, new effective, safe and affordable drugs are urgently needed for the treatment of these neglected diseases.
Inhibitors of the fungal sterol 14-demethylase enzyme (CYP51) and currently inhibitors of the orthologous enzyme T. cruzi CYP51 (TcCYP51) have demonstrated promising efficacy against Chagas disease in preclinical studies [10] [11] [12] [13] [14] [15] . However, in patients with chronic Chagas disease, the antifungal agent posaconazole was shown to be inferior to Bnz based on qPCR detection of T. cruzi DNA, measured 10 months after the end of treatment [16] . Moreover, in newly designed in vitro assays, nitroheterocyclic compounds were more efficacious trypanocidal agents compared to CYP51 inhibitors [17] , and in an acute murine infection model with Bnz and posaconazole administered concomitantly or in sequence, a positive interaction was observed between the two drugs [18] . These data suggest that inhibitors of sterol biosynthesis may not be as efficient as single chemotherapeutic agents against Chagas disease as they are against fungal infections, but they may be effective in combination with known or new nitroheterocyclic antichagasic agents. However, combining agents in vivo cannot always be effective due to differential pharmacokinetic behavior of each drug, failure to obtain an optimal required concentration and possible unexpected adverse effects. Combining CYP51 inhibition characteristics with bioreduction properties of a nitro-group in one molecule may offer a better solution in drug development against Chagas disease and other trypanosomatid-induced diseases.
This strategy has been successfully used in numerous occasions, including drugs for cancer, asthma and chronic obstructive pulmonary disease as well as neurodegenerative diseases [19] [20] [21] [22] .
We have demonstrated that a variety of 3-nitro-1H-1,2,4-triazole-based compounds exhibit excellent anti-T. cruzi activity both in vitro and in vivo, with several analogs also showing appreciable anti-T. b. rhodesiense activity in vitro [23] [24] [25] [26] [27] . Interestingly, 3-nitrotriazole-based 5 compounds are significantly more potent and less toxic than their 2-nitroimidazole-based counterparts [23] [24] [25] [26] [27] , with part of the trypanocidal activity being dependent on the parasite's expression of an oxygen-insensitive type I nitroreductase (NTR), an enzyme absent from most other eukaryotes [23, 24, 26, 27] . Type I NTR, via a series of 2 electron reduction reactions which lead to the production of toxic metabolites, is responsible for the trypanocidal activity of Nfx, Bnz and other nitroheterocyclic prodrugs in general [29] [30] [31] [32] . More recently, we have developed 3-nitrotriazole-based amides with a linear, rigid core, as well as 3-nitrotriazole-based carbinols (fluconazole analogs) which, in addition to being substrates for type I NTR, are also inhibitors of TcCYP51 [33] . These bifunctional agents exhibit promising anti-T. cruzi activity in vitro and in vivo and have excellent ADMET characteristics [33] .
In the current work we have expanded our search for more potent bifunctional antichagasic agents by investigating the role of an aryloxy-group in the scaffold of 3-nitrotriazole-based linear amides. Imidazole-based inhibitors of TcCYP51 with an aryloxy group in their scaffold have been previously identified [15] . Therefore, we hypothesized that 3-nitrotriazole-based analogs could potentially be inhibitors of this enzyme, in addition to their capacity of being substrates of type I NTRs.
Results and Discussion

Chemistry
The structures of synthesized compounds are shown in Table 1 . Their synthesis is straightforward, based on well-established chemistry and outlined in Scheme 1. Thus, amides 2-14 were obtained by nucleophilic substitution of the appropriate chloroacetamides 1a-h with the potassium salt of 3-nitro-1,2,4-triazole, 2-nitroimidazole or 1,2,4-triazole under refluxing conditions. Chloroacetamides 1a-h were prepared from appropriate, commercially available aryl/alkylamines and chloroacetyl chloride in the presence of triethylamine at room temperature. 
SAR analysis of antichagasic activity
The unsubstituted 3-nitrotriazole-based aryloxy-phenylamide 2 was a very potent anti-T. cruzi agent displaying an IC 50 of 65 nM against this parasite, 31-fold lower than that observed using Bnz, and having a SI of 1416. When a p-chloro group was introduced in the terminal phenyl of 2, the anti-T. cruzi potency increased by 8-fold and the SI by 2.6 in analog 3. Therefore, compound 3 was 254-fold more active than Bnz, and represents the most potent analog in this series. This increase in potency may be related to the increased lipophilicity of 3 compared to 2 (Table 1) . However, the presence of the nitro-group was far more important for activity than lipophilicity. Therefore, the des-nitro analog of 3, compound 5, albeit more lipophilic than 3, was only moderately active against T. cruzi, while its increased lipophilicity resulted in an unfavorable SI (<50). The fact that compound 5 demonstrated moderate activity against T. cruzi also indicates an alternative mechanism of action, independent of nitroreduction.
The fluoro-analog of 3, compound 4, was also more potent against T. cruzi than the unsubstituted compound 2, with an IC 50 value of 36 nM and a SI of 1954. However, 4 was 4.5-fold less potent than 3, presumably due to its lower lipophilicity, but still 56-fold more potent than Bnz (Table 1) .
To better understand the role that the ether link in 3 plays in mediating anti-T. cruzi activity, we included some biphenyl/biaryl compounds in the study. The biphenyl compound 6 has been described before by our group [33] . Compound 6, which shares a similar lipophilicity with its aryloxy-analog 3, was also very potent and selective against T. cruzi, however its potency was ca. 5.6-fold lower than that of 3, signifying the importance of the ether link in the core of these compounds for anti-T. cruzi activity. Similarly, the biphenyl compound 7 was about 2.8-fold less potent against T. cruzi compared to the unsubstituted aryloxy-compound 2 and 4-fold less potent than 6. In the latter case the drop in activity of 7 may be related to its significantly lower lipophilicity compared to 6 rather than the meta-position of the terminal phenyl group.
When the second phenyl ring in 7 was replaced with a pyrimidine ring in 8, the anti-T. cruzi activity was reduced by a factor of 14, despite the fact that both 7 and 8 share a similar clogP value. However, a greater PSA value in 8 may negatively affect permeability and thus activity [35] .
Replacing the phenoxy-group of 2 with a benzyl-group in 9 did not affect anti-T. cruzi activity. However, the SI of 9 was reduced >2.5, due to higher toxicity in host cells and was independent of lipophilicity since both compounds share a similar clogP value (Table 1) .
Inserting an oxygen in 9 to obtain the benzyloxy-analog 10 increased anti-T. cruzi activity and selectivity compared to both analog compounds 9 and 2, consistent with an increase in the lipophilicity of 10. In addition, 10 was about 2-fold less toxic than 9, presumably due to its slightly greater PSA value which may decrease permeability [35] . Furthermore, when the anilino-ring of 9 was replaced with a 4-piperidine-amino ring in 11, disturbance in the planarity 
SAR analysis of anti-T. brucei activity
Moderate activity was observed against BSF of T. b. rhodesiense with several analogs (2-4, 6, 9, 10, 13). Only the 3-nitrotriazole-based biphenylamide 6, however, demonstrated an acceptable selectivity (>100). Interestingly, there was relatively good correlation between anti-T. cruzi and anti-T. b. rhodesiense activity (R 2 = 0.77) among nitrotriazoles active against both parasites ( contrast to its 4-biphenyl analog 6, which displayed moderate activity and selectivity. Similarly, the 4-phenyl-pyrimidine amide 8 was inactive against T. b. rhodesiense. Once again, the desnitro analog of 3, compound 5, was deemed "inactive" against T. b. rhodesiense based on the TDR criteria, although the trypanocidal effect it did display made it more potent than the nitrocompounds 7 and 8, suggesting that the latter two may not be such good substrates for TbNTR.
SAR analysis of anti-L. donovani activity
This is the first report of 3-nitrotriazole-and 2-nitroimidazole-based compounds demonstrating selective anti-L. donovani activity. If we consider the active/moderately active 3-nitrotriazolebased analogs with the exception of 10, there was a relatively good correlation between anti-T.
cruzi and anti-L. donovani activity (R 2 = 0.82), whereas in the case of compounds with better structural similarity we observe an even better correlation, although the number of analogs in these cases is inadequate for correlations. In addition, increasing lipophilicity resulted in an increased anti-L. donovani activity (Table 1) . Chloro-substitution was more beneficial for activity than fluoro-or no substitution (compare 2, 3 and 4, as well as 12-14). The ether link in the core was more beneficial for activity than the methylene-or methylenoxy-link (2 vs 9 and 10)
or no link at all (3 vs 6). Disturbance in the planarity of the core in 11, or deletion of the nitro 13 group in 5, abolished anti-L. donovani activity. Similarly, replacement of the middle phenyl ring in 7 with a pyrimidine ring in 8, resulted in abolishment of the anti-L. donovani activity (Table   1) . Two 3-nitrotriazoles (4 and 6) and one 2-nitroimidazole (13) demonstrated similar activity to the reference compound miltefosine, whereas the 3-nitrotriazole-based p-chlorophenyloxyphenyl amide 3 was ca. 4.8-fold more potent than miltefosine, with a SI of 853. Compounds 2, 12 and 14 were selectively active against this parasite at nM concentrations, but slightly less potent than miltefosine. Finally, compounds 7, 9 and 10 were moderately active and with acceptable selectivity against the parasite (Table 1) . If we compare the corresponding 3-nitrotriazole-based and 2-nitroimidazole-based analogs, the former were 1.6 to 4-fold more active than the latter against L. donovani parasites (2 vs 12, 3 vs 13 and 4 vs 14). (36) , since it takes into account host cell-mediated effects (Table 2) . Despite activity against L. donvani axenic amastigotes, the 3-nitrotriazole-based analogs (2-4, 6 and 9) were not particularly active in infected macrophages, whereas the 2-nitroimidazole-based analogs (12) (13) (14) demonstrated moderate activity (IC 50 <20 μM) in this assay. Reduced intracellular activity might be associated with metabolic stability of the compounds in the macrophages or permeability issues, although permeability studies through Caco-2 cells with some analogs did not indicate any permeability problems.
Involvement of type I Nitroreductase
Representative analogs from Table 1 were evaluated as substrates of purified, recombinant trypanosomal NTRs and compared to benznidazole (Table 3) . Enzyme specific activity was measured as oxidized NADH per min per mg of protein. All tested compounds were excellent substrates of both TcNTR and TbNTR and metabolized by the T. cruzi enzyme at rates comparable or better than that of Bnz. However, the same analogs were metabolized by TbNTR at rates 1.6 to 2.2-fold higher than that of Bnz (Table 3) . When these studies were extended to NTR-overexpressing T. b. brucei were ca. 2-to 5-fold more sensitive to most of the tested compounds with 6 being the exception (Table 4) . However, there was no good correlation between TbNTR/TcNTR enzymatic activity and specific antitrypanosomal activity. This, coupled with the modest fold difference in susceptibility observed between cells expressing different levels of TbNTR in comparison to the larger changes noted when using other nitroheterocycles such as Nfx, indicates that this oxidoreductase may not be the only activator of the aryloxy-phenylamide prodrug within the parasite or that other factors (e.g. permeability into mitochondrion, compound stability and pharmacokinetic factors in general) may play a role in the antiparasitic activities. 
TcCYP51 inhibition
Azole-based scaffolds are effective inhibitors of the T. cruzi enzyme sterol 14α-demethylase, TcCYP51 [37] . In addition, aryloxybenzylimidazoles have been described as CYP51 inhibitors [15] . Therefore, in silico docking studies were performed by using the ligand binding pocket of the crystal structure of 4H6O sterole-14 demethylase and Glide docking protocols, to investigate whether or not the present compounds bind to the protein as the reference compound 15 ( Fig. 1) [15] . The docking scores, which were a function of -logKd, are shown in Table 5 . Table 5 . Docking scores of compounds in Table 1 and reference 15, in the ligand binding pocket of 4H6O sterole-14 demethylase. The score is a function of -logKd.
The 3-nitrotriazole-based aryloxyphenylamides 2-4 showed a higher docking score than the reference compound 15, whereas the more rigid 3-nitrotriazole-based biphenylamide 6 showed a similar docking score with 15. The rest of the compounds demonstrated docking scores lower than compound 15, with compound 5 (the des-nitro analog of 3) showing the lowest docking score ( Table 5 ). Examples of docked poses for compounds 3 and 15 are given in Fig. 1 A distance of 2.0 and 2.76 Å is shown between the iron atom and the corresponding nitrogen atom for compounds 3 and 15, respectively. The docking score seems to be affected primarily by the distance between the N4 of the nitrotriazole ring and the iron atom of the heme in the active site of the enzyme, whereas the orientation of the core group of each molecule can change significantly, making a SAR correlation much more complicated in this case.
There was good correlation between anti-T. cruzi activity (IC 50 values against T. cruzi) and docking score (Fig. 2) , suggesting that at least for compounds 2-4 and 6 the antichagasic activity may be also related to T. cruzi CYP51 inhibition, an assumption than needs to be verified. 
In vivo antichagasic activity
The most active compounds (3, 4 and 6) against T. cruzi in vitro were evaluated for in vivo antichagasic activity by using an acute T. cruzi infected murine model. Bnz was used in parallel as a positive control. Groups of 5 mice/group were treated i.p. for 10 consecutive days with each compound, at 13 mg/kg/day. In our previous work with 3-nitrotriazole-based rigid amides we have seen in vivo antichagasic activity at daily doses of 15 mg/kg, therefore we decided to use a slightly lower dose for the present tested analogs which demonstrate in vitro anti-T. cruzi activity at low nM concentrations (Table 1 ). The mean ratio of parasite levels was calculated after 5 and 10 days of treatment. The data are summarized in Fig. 3 and images are presented in Fig. 4 . All tested compounds weren't toxic at the given dose and time-frame and all, including Bnz, reduced the parasite load to undetectable levels (Fig. 4) after 5 days of treatment with statistical significance (p < 0.0001).
Conclusions:
3-Nitrotriazole-based aryloxyphenylamides are very potent and selective anti-T. cruzi agents both in vitro and in vivo, being able to reduce the parasite load to undetectable limits after just 5 days of treatment of infected mice, at the very small i.p. dose of 13 mg/kg/day (Figures 3 and 4) . (36) . Therefore, this scaffold should be further explored for lead drug optimization.
Both types of compounds act as substrates for trypanosomal type I NTR, whereas the 3-nitrotriazole-based analogs demonstrated slightly better docking scores for 4H6O sterol-14 demethylase than the reference compound 15, suggesting that the antichagasic properties of these compounds may be partially attributed to T. cruzi CYP51 inhibition, but this needs to be confirmed with enzymatic studies.
Finally, although the present compounds should be evaluated for mutagenicity/genotoxicity due to their nitro group, it is worth mentioning that previous studies have shown that 3-nitrotriazole-based amides are not mutagenic compared to their 2-nitroimidazole-based analogs [26] , and do not cause developmental toxicity in zebrafish [28] . Therefore, 3-nitrotriazole-based aryloxyphenylamides constitute a new generation of potentially effective and more affordable antichagasic agents in humans.
Experimental
Chemistry
General
All starting materials and solvents were purchased from Sigma-Aldrich (Milwaukee, WI), were of research-grade quality and used without further purification. Solvents used were anhydrous and the reactions were carried out under a nitrogen atmosphere and exclusion of moisture.
Melting points were determined by using a Mel-Temp II Laboratory Devices apparatus (Holliston, MA) and are uncorrected. Proton NMR spectra were obtained on a Varian Inova-500
or an Agilent Hg-400 spectrometer at 500 or 400 MHz, respectively, and are referenced to Me 4 Si or to the corresponding solvent, if the solvent was not CDCl 3 . High-resolution electrospray ionization (HRESIMS) mass spectra were obtained on a Agilent 6210 LC-TOF mass spectrometer at 11000 resolution. Thin-layer chromatography was carried out on aluminum oxide N/UV 254 or polygram silica gel G/UV 254 coated plates (0.2 mm, Analtech, Newark, DE).
Chromatography was carried out on preparative TLC alumina GF (1000 microns) or silica gel GF (1500 microns) plates (Analtech). All compounds were purified by preparative TLC chromatography on silica gel or alumina plates and also checked by HPLC (Agilent 1100) coupled to mass spectrometry (MS) and ultraviolet (UV) absorbance detectors. Purity was determined by comparing the area under the curve of the test compound peak to the combined areas of all peaks in the chromatogram, excluding DMSO and any peaks appearing in blank runs.
Priority reporting was given to the UV traces (since mass spectrometer response can vary widely depending on a given compound's ease of ionization). Purity of compounds lacking UV activity was reported using mass spectrometry detection. Purity was ≥ 95% purity for all analogs.
Synthesis of chlorides 1a-h:
Some of the chlorides 1a-h are known in the literature and others are unknown or known through 24 chemical libraries but without any reference. The synthesis and spectroscopic data of 1a-h are provided in the supporting material.
General Synthetic Procedure of amides 2-14:
The potassium salt of 3-nitro-1,2,4-triazole or 2-nitroimidazole or 1,2,4-triazole (1 eq) was formed in CH 3 CN (6-10 mL), by refluxing with KOH (1.2 eq) for 30 min. To this suspension, 1a-h (1.1 eq) was added and the reaction mixture was refluxed under a nitrogen atmosphere for 9 h. In certain cases, 1a-h was added in CH 3 CN solution. The reaction mixture was checked by TLC for completion of the reaction and the solvent was evaporated. The residue was dissolved in ethyl acetate and the inorganic salts were filtered away. Upon preparative TLC (silica gel or alumina, depending on the mobility of the major band;
ethyl acetate-petroleum ether), the desired product was obtained usually as a powder. Purity was checked also by HPLC and it was > 95%. 
2-(3-nitro-1H-1,2,4-triazol-1-yl)-N-(4-phenoxyphenyl]acetamide
N-[4-(4-chlorophenoxy)phenyl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (3):
N-([1,1'-biphenyl]-3-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide
2-(2-nitro-1H-imidazol-1-yl)-N-(4-phenoxyphenyl]acetamide
N-[4-(4-chlorophenoxy)phenyl]-2-(2-nitro-1H-imidazol-1-yl)acetamide
Biological evaluation.
In vitro screening:
In vitro activity against T. cruzi, T. b. rhodesiense, L. donovani and cytotoxicity assessment using L6 cells (rat skeletal myoblasts) was determined using a 96-well plate format as previously described [38] . Data were analyzed with the graphic program Softmax Pro (Molecular Devices, Sunnyvale, CA, USA), which calculated IC 50 values by linear regression from the sigmoidal dose inhibition curves.
Activity against Leishmania donovani intracellular amastigotes; macrophage assay:
Mouse peritoneal macrophages (4 x 10 4 in 100 µL RPMI 1640 medium with 10% heatinactivated FBS) were seeded into wells of Lab-tek 16-chamber slides. After 24 hrs 1.2 x 10 5 amastigote Leishmania donovani in 100 µL were added. The amastigotes were taken from an axenic amastigote culture grown at pH 5.4. Four hrs later the medium containing free amastigote forms was removed and replaced by fresh medium. Next day the medium was replaced by medium containing different compound dilutions. Parasite growth in the presence of the drug was compared to control wells. After 96 hours of incubation the medium was removed and the slides fixed with methanol for 10 min followed by a staining with a 10% Giemsa solution.
Infected and non-infected macrophages were counted for the control cultures and the ones exposed to the serial drug dilutions. The infection rates were determined. The results were expressed as % reduction in parasite burden compared to control wells, and the IC 50 calculated by linear regression analysis [39] .
In vitro T. brucei brucei antiproliferating assays and susceptibility studies.
The BSF of T. brucei brucei parasites were seeded at 1 x 10 3 ml -1 in 200 µL of growth medium containing different concentrations of nitroheterocycle. Where appropriate, induction of the TbNTR was carried out by adding tetracycline (1 µg/mL). After incubation for 3 days at 37 o C, 20 µL of Alamar blue was added to each well and the plates incubated for a further 16 h. The cell density of each culture was determined as described before [29] and the IC 50 established.
Enzymatic activity studies with Type I NTRs.
Recombinant TbNTR and TcNTR were prepared and assayed as previously described [40, 41] . The specific activity of purified his-tagged TbNTR was assessed spectrophotometrically at 340 nm using various nitrotriazole substrates (100 µM) and NADH (100 µM) and expressed as nmol NADH oxidized min -1 mg -1 of enzyme.
Molecular Modeling studies: Docking into the active site of 4H6O sterole-14 alpha demethylase.
The crystal structure of CYP51 (4H6O.pdb) which is available in protein database was imported for the analysis and found to be suitable for the docking experiments as there are no missing atoms found in the active site pocket of the enzyme. Moreover, the "b" values of the atoms are well within the average value of the crystal structure. 4H6O.pdb was validated with MolProbity 
In vivo antichagasic activity assessment of selected compounds:
For in vivo studies, a Brazilian strain trypomastigotes from transgenic T. cruzi parasites expressing firefly luciferase were used as described before [26] . Briefly, parasites were injected in Balb/c mice (10 5 trypomastigotes per mouse) and three days later mice were anesthesized by inhalation of isofluorane, followed by an injection with 150 mg/kg of D-luciferin potassium-salt in PBS. Mice were imaged 5 to 10 min after injection of luciferin with an IVIS 100 (Xenogen,
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Alameda, CA) and the data acquisition and analysis were performed with the software LivingImage (Xenogen) as described before [43] . Treatment with test compounds was started 4 days after infection at 13 mg/kg/day x 10 days, given i.p. The vehicle control was 2% methylcellulose + 0.5% Tween 80 and groups of 5 mice/group were used. Mice were imaged after 5 and 10 days of treatment. The ratio of parasite levels was calculated for each animal dividing the luciferase signal after treatment by the luciferase signal on the first imaging (before treatment). Mean values of all animals in each group  SD were used for plotting.
